Cipla Ltd.

Cipla has reportedly entered into agreement with Hetero to launch Darbepoetin Alfa in India. Darbepoetin Alfa is a synthetic form of erythropoietin, clinically proven to stimulate erythropoiesis (increased hemoglobin levels) for patients with anemia due to chronic kidney disease.

Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries.